{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:12:13Z","timestamp":1790745133787,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["FKZ 8033801805"],"award-info":[{"award-number":["FKZ 8033801805"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007821","name":"Tartu \u00dclikool","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["PCT\/EP2022\/061735"],"award-info":[{"award-number":["PCT\/EP2022\/061735"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ymthe.2022.10.011","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T02:30:58Z","timestamp":1666837858000},"page":"374-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection"],"prefix":"10.1016","volume":"31","author":[{"given":"Verena","family":"Kr\u00e4hling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Erbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kupke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin C.","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Dietzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Halwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Sauerhering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia","family":"Arag\u00e3o-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Moreno Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Witzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-9350","authenticated-orcid":false,"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.10.011_bib1","doi-asserted-by":"crossref","first-page":"12746","DOI":"10.1073\/pnas.1507442112","article-title":"Global biogeography of human infectious diseases","volume":"112","author":"Murray","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.10.011_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.10.011_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin","volume":"90","author":"Brazzoli","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient induction of T\u00a0cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.10.011_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.10.011_bib6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/0264-410X(94)90074-4","article-title":"Self-replicating Semliki Forest virus RNA as recombinant vaccine","volume":"12","author":"Zhou","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.10.011_bib8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/14760584.2019.1698952","article-title":"Ebola vaccine trials: progress in vaccine safety and immunogenicity","volume":"18","author":"Matz","year":"2019","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.10.011_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.10.011_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.10.011_bib11","doi-asserted-by":"crossref","first-page":"e1009937","DOI":"10.1371\/journal.ppat.1009937","article-title":"The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway","volume":"17","author":"Furuyama","year":"2021","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2022.10.011_bib12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/pathogens10101330","article-title":"Structural and functional aspects of ebola virus proteins","volume":"10","author":"Jain","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.ymthe.2022.10.011_bib13","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1016\/j.vaccine.2020.04.034","article-title":"An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design","volume":"38","author":"Herst","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.10.011_bib14","doi-asserted-by":"crossref","first-page":"E7578","DOI":"10.1073\/pnas.1806200115","article-title":"Analysis of CD8+ T\u00a0cell response during the 2013-2016 ebola epidemic in West Africa","volume":"115","author":"Sakabe","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.10.011_bib15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/14760584.2014.885841","article-title":"Ebola virus vaccines: an overview of current approaches","volume":"13","author":"Marzi","year":"2014","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.10.011_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/2051013615611017","article-title":"Clinical development of Ebola vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Ther. Adv. Vaccin."},{"key":"10.1016\/j.ymthe.2022.10.011_bib18","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.3389\/fmicb.2017.02662","article-title":"Alphavirus replicon DNA vectors expressing ebola GP and VP40 antigens induce humoral and cellular immune responses in mice","volume":"8","author":"Ren","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib19","article-title":"Protective CD8+ T\u00a0cell response induced by modified vaccinia virus ankara delivering ebola virus nucleoprotein","volume":"10","author":"Kupke","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.10.011_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/srep01206","article-title":"The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells","volume":"3","author":"Nanbo","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.10.011_bib21","doi-asserted-by":"crossref","first-page":"11779","DOI":"10.1128\/JVI.01525-12","article-title":"Inclusion bodies are a site of ebolavirus replication","volume":"86","author":"Hoenen","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1743-422X-8-11","article-title":"Full-length Ebola glycoprotein accumulates in the endoplasmic reticulum","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2022.10.011_bib23","doi-asserted-by":"crossref","first-page":"e1004509","DOI":"10.1371\/journal.ppat.1004509","article-title":"Shed GP of Ebola virus triggers immune activation and increased vascular permeability","volume":"10","author":"Escudero-P\u00e9rez","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2022.10.011_bib24","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.10.011_bib25","article-title":"An Update on Self-Amplifying mRNA Vaccine Development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ymthe.2022.10.011_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa043540","article-title":"Dose sparing with intradermal injection of influenza vaccine","volume":"351","author":"Kenney","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.10.011_bib27","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design","volume":"198","author":"Pepini","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib29","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa043555","article-title":"Serum antibody responses after intradermal vaccination against influenza","volume":"351","author":"Belshe","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.10.011_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jconrel.2021.12.008","article-title":"The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency","volume":"342","author":"Anderluzzi","year":"2022","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2022.10.011_bib31","doi-asserted-by":"crossref","first-page":"642788","DOI":"10.3389\/falgy.2021.642788","article-title":"Antigen uptake after intradermal microinjection depends on antigen nature and formulation, but not on injection depth","volume":"2","author":"Leboux","year":"2021","journal-title":"Front. Allergy"},{"key":"10.1016\/j.ymthe.2022.10.011_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/viro.1998.9176","article-title":"DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge","volume":"246","author":"Vanderzanden","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2022.10.011_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect Guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2022.10.011_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-based vaccines elicit robust immune responses and protect Guinea pigs from ebola virus disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.10.011_bib35","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.10.011_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.coviro.2020.08.003","article-title":"A new generation of vaccines based on alphavirus self-amplifying RNA","volume":"44","author":"Ballesteros-Briones","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/pharmaceutics13020140","article-title":"Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants","volume":"13","author":"Bouazzaoui","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2022.10.011_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3201\/eid0805.010284","article-title":"Evaluation in nonhuman primates of vaccines against Ebola virus","volume":"8","author":"Geisbert","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.10.011_bib39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fmicb.2013.00267","article-title":"Animal models for Ebola and Marburg virus infections","volume":"4","author":"Nakayama","year":"2013","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect Guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2022.10.011_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in filovirus vaccine development: evaluating the potential for clinical use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.ymthe.2022.10.011_bib42","first-page":"253","article-title":"Animal models of ebolavirus infection","volume":"67","author":"St Claire","year":"2017","journal-title":"Comp. Med."},{"key":"10.1016\/j.ymthe.2022.10.011_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.coviro.2013.01.001","article-title":"Animal models for highly pathogenic emerging viruses","volume":"3","author":"Safronetz","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib44","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1128\/JVI.79.22.14189-14196.2005","article-title":"Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins","volume":"79","author":"Olinger","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib45","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/JVI.75.6.2660-2664.2001","article-title":"Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein","volume":"75","author":"Wilson","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib46","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.10.011_bib47","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2022.10.011_bib48","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.10.011_bib49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/CVI.00431-07","article-title":"Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections","volume":"15","author":"Swenson","year":"2008","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib50","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1128\/JVI.00105-07","article-title":"Successful topical respiratory tract immunization of primates against Ebola virus","volume":"81","author":"Bukreyev","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib51","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/JVI.80.5.2267-2279.2006","article-title":"A single intranasal inoculation with a paramyxovirus-vectored vaccine protects Guinea pigs against a lethal-dose Ebola virus challenge","volume":"80","author":"Bukreyev","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib52","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.10.011_bib53","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.10.011_bib54","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/gt.2010.52","article-title":"Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in\u00a0vivo","volume":"17","author":"Kuhn","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.10.011_bib55","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1006\/abio.1994.1360","article-title":"In\u00a0vitro transcription: preparative RNA yields in analytical scale reactions","volume":"220","author":"Pokrovskaya","year":"1994","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymthe.2022.10.011_bib56","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1128\/JVI.00051-06","article-title":"Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24","volume":"80","author":"Hoenen","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib57","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1128\/JVI.01245-08","article-title":"Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity","volume":"83","author":"Kr\u00e4hling","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00430-015-0438-6","article-title":"Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus","volume":"205","author":"Kr\u00e4hling","year":"2016","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00430-003-0204-z","article-title":"Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus","volume":"193","author":"Lucht","year":"2004","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib60","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1128\/JVI.01186-15","article-title":"Differences in processing determinants of nonstructural polyprotein and in the sequence of nonstructural protein 3 affect neurovirulence of Semliki forest virus","volume":"89","author":"Saul","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib61","doi-asserted-by":"crossref","first-page":"12277","DOI":"10.1128\/JVI.78.22.12277-12287.2004","article-title":"Multivesicular bodies as a platform for formation of the Marburg virus envelope","volume":"78","author":"Kolesnikova","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2022.10.011_bib62","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.cell.2020.04.022","article-title":"Microbiota-induced type I interferons instruct a poised basal state of dendritic cells","volume":"181","author":"Schaupp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.10.011_bib63","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"264","author":"M\u00fcller","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.10.011_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2022.10.011_bib65","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41591-019-0602-4","article-title":"Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV","volume":"25","author":"Ehrhardt","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.10.011_bib66","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1074-7613(00)00052-2","article-title":"Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex","volume":"13","author":"Slansky","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2022.10.011_bib67","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1128\/JCM.39.11.4125-4130.2001","article-title":"Development and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan","volume":"39","author":"Gibb","year":"2001","journal-title":"J.\u00a0Clin. Microbiol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:51:51Z","timestamp":1778521911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622006232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1525001622006232"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.10.011","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}